Glial activation and glucose metabolism in a transgenic amyloid mouse model: A triple-tracer PET study

Journal of Nuclear Medicine

Volumn 57, Issue 6, 2016, Pages 954-960

  Brendel, Matthias ^a   Probst, Federico ^a   Jaworska, Anna ^b   Overhoff, Felix ^a   Korzhova, Viktoria ^b   Albert, Nathalie L ^a   Beck, Roswitha ^a   Lindner, Simon ^a   Gildehaus, Franz Josef ^a   Baumann, Karlheinz ^c   Bartenstein, Peter ^a   Kleinberger, Gernot ^a,b   Haass, Christian ^a,b   Herms, Jochen ^a,b   Rominger, Axel ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

18FGE180; Alzheimer's disease; Neuroinflammation; Small animal PET; TSPO

Indexed keywords

AMYLOID BETA PROTEIN; FLUORINE 18; FLUORINE GE 180 F 18; GLUCOSE; UNCLASSIFIED DRUG; CARBAZOLE DERIVATIVE; GE-180; TRACER;

AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CELL ACTIVATION; CONTROLLED STUDY; EX VIVO STUDY; GLIA CELL; GLUCOSE METABOLISM; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MICROGLIA; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TRANSGENIC MOUSE; WHITE MATTER; WILD TYPE; AMYLOIDOSIS; ANIMAL; C57BL MOUSE; DIAGNOSTIC IMAGING; DISEASE MODEL; HUMAN; METABOLISM; PATHOLOGY; PROCEDURES; STANDARD; STANDARDS;

AMYLOIDOSIS; ANIMALS; CARBAZOLES; DISEASE MODELS, ANIMAL; GLUCOSE; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; REFERENCE STANDARDS;

EID: 84973650175     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.167858     Document Type: Article

References (31)

1. Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM. Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement. 2008;4:316-323.
2. Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012;8:S1-S68.
3. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14:388-405.
4. McGeer PL, McGeer EG. Mechanisms of cell death in Alzheimer disease: immunopathology. J Neural Transm Suppl. 1998;54:159-166.
5. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol (Berl). 2009;118:5-36.
6. Hall AM, Roberson ED. Mouse models of Alzheimer's disease. Brain Res Bull. 2012;88:3-12.
7. Teipel SJ, Buchert R, Thome J, Hampel H, Pahnke J. Development of Alzheimerdisease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. Prog Neurobiol. 2011;95:547-556.
8. Zimmer ER, Parent MJ, Cuello AC, Gauthier S, Rosa-Neto P. MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research. Trends Neurosci. 2014;37:629-641.
9. Manook A, Yousefi BH, Willuweit A, et al. Small-animal PET imaging of amyloidbeta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS One. 2012;7:e31310.
10. Rominger A, Brendel M, Burgold S, et al. Longitudinal assessment of cerebral beta-amyloid deposition in mice overexpressing Swedish mutant beta-amyloid precursor protein using 18F-florbetaben PET. J Nucl Med. 2013;54:1127-1134.
11. Rapic S, Backes H, Viel T, et al. Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease. Neurobiol Aging. 2013;34:351-354.
12. Rodriguez-Vieitez E, Ni R, Gulyas B, et al. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. Eur J Nucl Med Mol Imaging. 2015;42:1119-1132
13. Sérrière S, Tauber C, Vercouillie J, et al. Amyloid load and translocator protein 18 kDa in APPswePS1-dE9 mice: a longitudinal study. Neurobiol Aging. 2015;36:1639-1652.
14. Cumming P, Pedersen MD, Minuzzi L, et al. Distribution of PK11195 binding sites in porcine brain studied by autoradiography in vitro and by positron emission tomography. Synapse. 2006;59:418-426.
15. Dickens AM, Vainio S, Marjamaki P, et al. Detection of microglial activation in an acute model of neuroinflammation using PET and radiotracers 11C-(R)- PK11195 and 18F-GE-180. J Nucl Med. 2014;55:466-472.
16. Wickstrøm T, Clarke A, Gausemel I, et al. The development of an automated and GMP compliant FASTlab synthesis of [18F]GE-180; a radiotracer for imaging translocator protein (TSPO). J Labelled Comp Radiopharm. 2014;57:42-48.
17. Brendel M, Jaworska A, Griessinger E, et al. Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models. PLoS One. 2015;10:e0116678.
18. Richards JG, Higgins GA, Ouagazzal AM, et al. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci. 2003;23: 8989-9003.
19. Ozmen L, Albientz A, Czech C, Jacobsen H. Expression of transgenic APP mRNA is the key determinant for beta-amyloid deposition in PS2APP transgenic mice. Neurodegener Dis. 2009;6:29-36.
20. Brendel M, Delker A, Rotzer C, et al. Impact of partial volume effect correction on cerebral beta-amyloid imaging in APP-Swe mice using [18F]-florbetaben PET. Neuroimage. 2014;84:843-853.
21. Overhoff F, Brendel M, Jaworska A, et al. Automated spatial brain normalization and hindbrain white matter reference tissue give improved [18F]-florbetaben PET quantitation in Alzheimer's model mice. Front Neurosci. 2016;10:45.
22. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840.
23. Pedersen MD, Minuzzi L, Wirenfeldt M, et al. Up-regulation of PK11195 binding in areas of axonal degeneration coincides with early microglial activation in mouse brain. Eur J Neurosci. 2006;24:991-1000.
24. Lyoo CH, Ikawa M, Liow JS, et al. Cerebellum can serve as a pseudo-reference region in Alzheimer disease to detect neuroinflammation measured with PET radioligand binding to translocator protein. J Nucl Med. 2015;56:701-706.
25. Constantinescu CC, Mukherjee J. Performance evaluation of an Inveon PET preclinical scanner. Phys Med Biol. 2009;54:2885-2899.
26. Liu B, Le KX, Park MA, et al. In vivo detection of age- and disease-related increases in neuroinflammation by 18F-GE180 TSPO microPET imaging in wildtype and Alzheimer's transgenic mice. J Neurosci. 2015;35:15716-15730.
27. Poisnel G, Herard AS, El Tannir El Tayara N, et al. Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease. Neurobiol Aging. 2012;33:1995-2005.
28. Rojas S, Herance JR, Gispert JD, et al. In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography. Neurobiol Aging. 2013;34:1790-1798.
29. Ewers M, Brendel M, Rizk-Jackson A, et al. Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. Neuroimage Clin. 2014;4:45-52.
30. Caroli A, Lorenzi M, Geroldi C, et al. Metabolic compensation and depression in Alzheimer's disease. Dement Geriatr Cogn Disord. 2010;29:37-45.
31. Brendel M, Jaworska A, Herms J, et al. Amyloid-PET predicts inhibition of de novo plaque formation upon chronic gamma-secretase modulator treatment. Mol Psychiatry. 2015;20:1179-1187.